These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 22087278)
61. Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from beta-cells through activation of GPR40. Schnell S; Schaefer M; Schöfl C Mol Cell Endocrinol; 2007 Jan; 263(1-2):173-80. PubMed ID: 17101212 [TBL] [Abstract][Full Text] [Related]
62. Multiple mechanisms of GW-9508, a selective G protein-coupled receptor 40 agonist, in the regulation of glucose homeostasis and insulin sensitivity. Ou HY; Wu HT; Hung HC; Yang YC; Wu JS; Chang CJ Am J Physiol Endocrinol Metab; 2013 Mar; 304(6):E668-76. PubMed ID: 23341496 [TBL] [Abstract][Full Text] [Related]
63. Discovery of novel free fatty acid receptor 1 agonists bearing triazole core via click chemistry. Li Z; Yang J; Wang X; Li H; Liu C; Wang N; Huang W; Qian H Bioorg Med Chem; 2016 Nov; 24(21):5449-5454. PubMed ID: 27624524 [TBL] [Abstract][Full Text] [Related]
64. Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles. Guo B; Guo S; Huang J; Li J; Li J; Chen Q; Zhou X; Xie X; Yang Y Bioorg Med Chem; 2018 Dec; 26(22):5780-5791. PubMed ID: 30392954 [TBL] [Abstract][Full Text] [Related]
66. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes. Yoshida S; Tanaka H; Oshima H; Yamazaki T; Yonetoku Y; Ohishi T; Matsui T; Shibasaki M Biochem Biophys Res Commun; 2010 Oct; 400(4):745-51. PubMed ID: 20816753 [TBL] [Abstract][Full Text] [Related]
67. [A New Pain Regulatory System via the Brain Long Chain Fatty Acid Receptor GPR40/FFA1 Signal]. Nakamoto K Yakugaku Zasshi; 2017; 137(2):199-204. PubMed ID: 28154332 [TBL] [Abstract][Full Text] [Related]
68. Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists. Jiang XW; Jiang BE; Liu H; Liu ZT; Hu LL; Liu M; Lu W; Zhang HK Eur J Med Chem; 2018 Oct; 158():123-133. PubMed ID: 30212763 [TBL] [Abstract][Full Text] [Related]
69. Preclinical characterization of 55P0251, a novel compound that amplifies glucose-stimulated insulin secretion and counteracts hyperglycaemia in rodents. Stadlbauer K; Brunmair B; Lehner Z; Adorjan I; Scherer T; Luger A; Bauer L; Fürnsinn C Diabetes Obes Metab; 2017 Aug; 19(8):1088-1096. PubMed ID: 28211608 [TBL] [Abstract][Full Text] [Related]
70. Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold. Li Z; Liu C; Yang J; Zhou J; Ye Z; Feng D; Yue N; Tong J; Huang W; Qian H Eur J Med Chem; 2019 Oct; 179():608-622. PubMed ID: 31279294 [TBL] [Abstract][Full Text] [Related]
71. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Chu ZL; Jones RM; He H; Carroll C; Gutierrez V; Lucman A; Moloney M; Gao H; Mondala H; Bagnol D; Unett D; Liang Y; Demarest K; Semple G; Behan DP; Leonard J Endocrinology; 2007 Jun; 148(6):2601-9. PubMed ID: 17289847 [TBL] [Abstract][Full Text] [Related]
72. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056 [TBL] [Abstract][Full Text] [Related]
73. Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists. Negoro N; Sasaki S; Ito M; Kitamura S; Tsujihata Y; Ito R; Suzuki M; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Tanaka T; Yasuma T; Momose Y J Med Chem; 2012 Feb; 55(4):1538-52. PubMed ID: 22242551 [TBL] [Abstract][Full Text] [Related]
74. Discovery of a novel potent GPR40 full agonist. Meegalla SK; Huang H; Martin T; Xu J; Zhao S; Liu J; Hall M; Gunnet J; Wang Y; Rady B; Silva J; Otieno M; Arnoult E; Paul Lee S; Pocai A; Player MR Bioorg Med Chem Lett; 2018 Feb; 28(4):720-726. PubMed ID: 29366647 [TBL] [Abstract][Full Text] [Related]
75. GPR120 agonists for the treatment of diabetes: a patent review (2014 present). Zhang X; Macielag MJ Expert Opin Ther Pat; 2020 Oct; 30(10):729-742. PubMed ID: 32799609 [TBL] [Abstract][Full Text] [Related]
76. Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet beta-cells: mediation by PLC and L-type Ca2+ channel and link to insulin release. Fujiwara K; Maekawa F; Yada T Am J Physiol Endocrinol Metab; 2005 Oct; 289(4):E670-7. PubMed ID: 15914509 [TBL] [Abstract][Full Text] [Related]
77. A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes. Chen Y; Song M; Riley JP; Hu CC; Peng X; Scheuner D; Bokvist K; Maiti P; Kahl SD; Montrose-Rafizadeh C; Hamdouchi C; Miller AR Pharmacol Res Perspect; 2016 Dec; 4(6):e00278. PubMed ID: 28097011 [TBL] [Abstract][Full Text] [Related]
78. Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode. Jurica EA; Wu X; Williams KN; Hernandez AS; Nirschl DS; Rampulla RA; Mathur A; Zhou M; Cao G; Xie C; Jacob B; Cai H; Wang T; Murphy BJ; Liu H; Xu C; Kunselman LK; Hicks MB; Sun Q; Schnur DM; Sitkoff DF; Dierks EA; Apedo A; Moore DB; Foster KA; Cvijic ME; Panemangalore R; Flynn NA; Maxwell BD; Hong Y; Tian Y; Wilkes JJ; Zinker BA; Whaley JM; Barrish JC; Robl JA; Ewing WR; Ellsworth BA J Med Chem; 2017 Feb; 60(4):1417-1431. PubMed ID: 28112924 [TBL] [Abstract][Full Text] [Related]
79. Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1. Xiong Y; Swaminath G; Cao Q; Yang L; Guo Q; Salomonis H; Lu J; Houze JB; Dransfield PJ; Wang Y; Liu JJ; Wong S; Schwandner R; Steger F; Baribault H; Liu L; Coberly S; Miao L; Zhang J; Lin DC; Schwarz M Mol Cell Endocrinol; 2013 Apr; 369(1-2):119-29. PubMed ID: 23403053 [TBL] [Abstract][Full Text] [Related]
80. Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents. Li Z; Chen Y; Zhou Z; Deng L; Xu Y; Hu L; Liu B; Zhang L Eur J Med Chem; 2019 Feb; 164():352-365. PubMed ID: 30605833 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]